Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy

We studied the serologic response to the BNT162b2 mRNA vaccine at four weeks after the second dose in patients with RRMS treated with rituximab with extended-interval dosing (n = 26). At four weeks, 73% of patients were seropositive. No patient without B cells at the first dose (n = 4) was seroposit...

Descripción completa

Detalles Bibliográficos
Autores principales: Rico, Audrey, Ninove, Laetitia, Maarouf, Adil, Boutiere, Clémence, Durozard, Pierre, Demortiere, Sarah, Saba Villarroel, Paola Mariela, Amroun, Abdennour, Fourié, Toscane, de Lamballerie, Xavier, Pelletier, Jean, Audoin, Bertrand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673883/
https://www.ncbi.nlm.nih.gov/pubmed/34925877
http://dx.doi.org/10.1177/20552173211062142
_version_ 1784615537167302656
author Rico, Audrey
Ninove, Laetitia
Maarouf, Adil
Boutiere, Clémence
Durozard, Pierre
Demortiere, Sarah
Saba Villarroel, Paola Mariela
Amroun, Abdennour
Fourié, Toscane
de Lamballerie, Xavier
Pelletier, Jean
Audoin, Bertrand
author_facet Rico, Audrey
Ninove, Laetitia
Maarouf, Adil
Boutiere, Clémence
Durozard, Pierre
Demortiere, Sarah
Saba Villarroel, Paola Mariela
Amroun, Abdennour
Fourié, Toscane
de Lamballerie, Xavier
Pelletier, Jean
Audoin, Bertrand
author_sort Rico, Audrey
collection PubMed
description We studied the serologic response to the BNT162b2 mRNA vaccine at four weeks after the second dose in patients with RRMS treated with rituximab with extended-interval dosing (n = 26). At four weeks, 73% of patients were seropositive. No patient without B cells at the first dose (n = 4) was seropositive. Four of seven (57%) patients with B-cell proportion >0% and ≤5% were seropositive. All patients with B-cell proportion >5% (n = 15) were seropositive. In all patients, quantitative ELISA measures after vaccination were correlated with B-cell counts measured before vaccination. In patients receiving rituximab, seropositivity after BNT162b2 mRNA vaccination emerged only after B-cell repopulation.
format Online
Article
Text
id pubmed-8673883
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-86738832021-12-16 Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy Rico, Audrey Ninove, Laetitia Maarouf, Adil Boutiere, Clémence Durozard, Pierre Demortiere, Sarah Saba Villarroel, Paola Mariela Amroun, Abdennour Fourié, Toscane de Lamballerie, Xavier Pelletier, Jean Audoin, Bertrand Mult Scler J Exp Transl Clin Brief Report We studied the serologic response to the BNT162b2 mRNA vaccine at four weeks after the second dose in patients with RRMS treated with rituximab with extended-interval dosing (n = 26). At four weeks, 73% of patients were seropositive. No patient without B cells at the first dose (n = 4) was seropositive. Four of seven (57%) patients with B-cell proportion >0% and ≤5% were seropositive. All patients with B-cell proportion >5% (n = 15) were seropositive. In all patients, quantitative ELISA measures after vaccination were correlated with B-cell counts measured before vaccination. In patients receiving rituximab, seropositivity after BNT162b2 mRNA vaccination emerged only after B-cell repopulation. SAGE Publications 2021-11-29 /pmc/articles/PMC8673883/ /pubmed/34925877 http://dx.doi.org/10.1177/20552173211062142 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Brief Report
Rico, Audrey
Ninove, Laetitia
Maarouf, Adil
Boutiere, Clémence
Durozard, Pierre
Demortiere, Sarah
Saba Villarroel, Paola Mariela
Amroun, Abdennour
Fourié, Toscane
de Lamballerie, Xavier
Pelletier, Jean
Audoin, Bertrand
Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy
title Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy
title_full Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy
title_fullStr Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy
title_full_unstemmed Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy
title_short Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy
title_sort determining the best window for bnt162b2 mrna vaccination for sars-cov-2 in patients with multiple sclerosis receiving anti-cd20 therapy
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673883/
https://www.ncbi.nlm.nih.gov/pubmed/34925877
http://dx.doi.org/10.1177/20552173211062142
work_keys_str_mv AT ricoaudrey determiningthebestwindowforbnt162b2mrnavaccinationforsarscov2inpatientswithmultiplesclerosisreceivinganticd20therapy
AT ninovelaetitia determiningthebestwindowforbnt162b2mrnavaccinationforsarscov2inpatientswithmultiplesclerosisreceivinganticd20therapy
AT maaroufadil determiningthebestwindowforbnt162b2mrnavaccinationforsarscov2inpatientswithmultiplesclerosisreceivinganticd20therapy
AT boutiereclemence determiningthebestwindowforbnt162b2mrnavaccinationforsarscov2inpatientswithmultiplesclerosisreceivinganticd20therapy
AT durozardpierre determiningthebestwindowforbnt162b2mrnavaccinationforsarscov2inpatientswithmultiplesclerosisreceivinganticd20therapy
AT demortieresarah determiningthebestwindowforbnt162b2mrnavaccinationforsarscov2inpatientswithmultiplesclerosisreceivinganticd20therapy
AT sabavillarroelpaolamariela determiningthebestwindowforbnt162b2mrnavaccinationforsarscov2inpatientswithmultiplesclerosisreceivinganticd20therapy
AT amrounabdennour determiningthebestwindowforbnt162b2mrnavaccinationforsarscov2inpatientswithmultiplesclerosisreceivinganticd20therapy
AT fourietoscane determiningthebestwindowforbnt162b2mrnavaccinationforsarscov2inpatientswithmultiplesclerosisreceivinganticd20therapy
AT delamballeriexavier determiningthebestwindowforbnt162b2mrnavaccinationforsarscov2inpatientswithmultiplesclerosisreceivinganticd20therapy
AT pelletierjean determiningthebestwindowforbnt162b2mrnavaccinationforsarscov2inpatientswithmultiplesclerosisreceivinganticd20therapy
AT audoinbertrand determiningthebestwindowforbnt162b2mrnavaccinationforsarscov2inpatientswithmultiplesclerosisreceivinganticd20therapy

Ejemplares similares